NOVMETAPHARMA CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20,500 KRW | +2.24% |
|
-.--% | -.--% |
More news
| 1 day | +2.24% |
1 year
13 010.00
22 900.00
3 years
8 950.0030 000.00
5 years
8 950.0056 000.00
10 years
8 810.0096 100.00
| Managers | Title | Age | Since |
|---|---|---|---|
Hoi-Yoon Jung
CEO | Chief Executive Officer | 45 | - |
Seon-Wook Hwang
CEO | Chief Executive Officer | 64 | 04/10/04 |
Heon-Jong Lee
BRD | Director/Board Member | 54 | 01/11/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Johan Auwerx
BRD | Director/Board Member | - | - |
Seon-Wook Hwang
CEO | Chief Executive Officer | 64 | 04/10/04 |
Heon-Jong Lee
BRD | Director/Board Member | 54 | 01/11/01 |
NovMetaPharma Co., Ltd. is a Korea-based company mainly engaged in the development and sale of pharmaceuticals. The Company operates its business through two segments. The New Drug Development segment is involved in the development and sale of diabetes treatment, obesity treatment, osteoporosis treatment, alzheimer's disease treatment, and autoimmune enhancers. The Health Functional Food segment is engaged in the manufacturing and sale of health functional food related to blood sugar, prostate health, comprehensive minerals, and cognitive improvement. It also produces and sells vinegar drinks. The Company distributes its products within the domestic market and to overseas markets, including America and China.
Calendar
24/05/2024
- Investor Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 136M | |
| +8.96% | 105B | |
| -1.43% | 104B | |
| +4.40% | 22.94B | |
| -12.15% | 22.34B | |
| -4.36% | 19.25B | |
| -39.98% | 17.08B | |
| -10.04% | 16.96B | |
| +6.79% | 14.16B | |
| +38.61% | 12.63B |
- Stock Market
- Equities
- A229500 Stock
